The Bio-Clock Reset Protocol — Sleep First, Epithalon and Thymalin as the Experiment
An honest version of the epithalon-plus-thymalin longevity protocol. Layer 0 is the part that actually resets a body clock: fixed wake time, morning light and a sleep baseline. Layer 1 is magnesium L-threonate, the only compound here with placebo-controlled human trials, all of them industry-linked and modest. Layer 2 is the pineal peptide epithalon and the thymus peptide thymalin, optional and labelled for what they are: one research group's cohorts, a mortality signal nobody has replicated, telomere data from cells in a dish, unapproved research peptides and community doses. Graded D to the peptide layer that gives the protocol its name.
Daily Schedule
Timing and dosage for each step
Layer 0 — two weeks before anything else: fixed wake time, morning daylight, a sleep diary or wearable baseline, and a basic panel (CBC, CRP, fasting glucose, HbA1c)
2 g
This is a measurement step, not a dose. The pineal story behind this protocol is a sleep and melatonin story, and nothing on this page competes with a regular wake time and morning light. The 2,000 mg shown is the Layer 1 dose that follows.
Layer 1 — evening, 1–2 hours before bed, from week 2
2 g
2,000 mg magnesium L-threonate (about 144 mg elemental magnesium). The one layer with randomized, placebo-controlled human trials: a 12-week trial in adults aged 50–70 with cognitive impairment (composite cognition p = 0.003) and a 6-week trial in 100 adults with poor sleep (overall cognition p = 0.043; self-rated sleep impairment better, ring-measured sleep unchanged). Both were run by or with the ingredient's makers. Grade C.
Layer 2 — OPTIONAL experimental layer, morning, subcutaneous, 10 consecutive days, no more than twice a year
10 mg
⚠️ No independent human trial. The human data come from one research network: a 6–8-year cohort of 266 older adults and two reports on older coronary patients followed for 12 and 15 years, all poorly reported. The telomere-lengthening claim comes from a cell-culture study, not from people. The 10 mg/day is the community convention; the published abstracts do not state a dose. Research peptide, not approved by the FDA or EMA. Skip this layer and the protocol stands.
Layer 2 — OPTIONAL, same 10-day window, only if you have a specific reason to run it alongside epithalon
10 mg
⚠️ Same research network, same 266-person cohort (published twice), plus a small COVID-19 add-on study without effect sizes. No systematic adverse-event reporting exists. Community dose, not a trial dose. Research peptide. Running two unapproved peptides at once means you cannot tell which one caused a side effect.
Read This Before the Protocol
Almost everything known about epithalon and thymalin in people comes from one research network. Researchers from two institutes in St. Petersburg and Kiev ran the cohorts and wrote the papers. A search of PubMed for an independent human trial of either one returns nothing. That does not make the findings false, but it means none of them has been checked by anyone without a stake in the answer.
The headline numbers are real, and they are weaker than they look. In the best-known paper, 266 older adults were followed for 6–8 years after receiving the peptides during the first 2–3 years. Mortality was reported 1.6–1.8 times lower with epithalamin, 2.0–2.1 times lower with thymalin and 2.5 times lower with both, compared with controls. The abstract does not describe how people were assigned to groups, what the controls received, or what dose was given, and the same cohort was published again in a second journal. Two further reports cover older patients with coronary disease given epithalamin. A 12-year randomized study reported 28% fewer deaths in the epithalamin group than in controls, and cardiovascular mortality two times lower. A 15-year comparison of 39 patients on epithalamin courses against 40 on standard care reported "significantly lower mortality", without a number in the abstract. Both tested epithalamin, the pineal extract, not synthetic epithalon, and neither tested thymalin. Earlier versions of this page attached the 12-year, 28% figures to the 266-person cohort and to the two peptides combined; they belong to the coronary study of epithalamin alone.
"Epithalon lengthens telomeres" is a cell-culture result. The study behind the claim added the peptide to fetal human fibroblasts in a dish and found telomerase activity and longer telomeres. No study has measured telomere length in people taking it.
So this page keeps the protocol, puts the one compound with placebo-controlled human data first, and labels the peptide layer as the experiment it is. The longer read on the peptide itself is Epitalon (AEDG): The Telomerase Guide; the thymus side is in Thymalin Protocol.
Layer 0 — Reset the Clock You Can Actually Reach
The rationale for epithalon is the pineal gland and melatonin. In the group's own before-and-after study in healthy elderly people, a course of epithalamin raised night-time melatonin in those whose levels started low and tended to lower it in those whose levels were normal. Whatever that study shows, the levers below move the same system with far better evidence, and they cost nothing:
| Lever | What to do for two weeks |
|---|---|
| Wake time | The same time every day, weekends included |
| Morning light | 10–20 minutes outdoors within an hour of waking |
| Evening light | Dim, warm light for the last two hours before bed |
| Baseline | A sleep diary or a wearable: sleep onset, wake-ups, how you feel at 10 a.m. |
| Bloods | CBC, CRP, fasting glucose and HbA1c, so later changes have a reference point |
If your sleep is the main complaint, the better-evidenced page is the Deep Sleep Stack, and magnesium threonate is its Layer 2. Do not take it twice.
Who This Is For, and Who Should Not Run It
For: adults over about 50 who want to try the peptide protocol they have read about and want to do it with eyes open: a sleep baseline first, one compound with human trials, then a time-limited, monitored peptide experiment.
Not for, without a clinician:
- Active cancer, or a history of it: a compound described as activating telomerase has an obvious theoretical concern, and no safety data answer it.
- Autoimmune disease or immunosuppressive treatment (thymalin is given to change immune function).
- Pregnancy or breastfeeding.
- Anyone under about 40: no study included younger adults.
- Anyone who cannot verify what is in a research-peptide vial. Purity and dose are not regulated.
The Layer Logic
| Layer | What | Evidence grade | Who |
|---|---|---|---|
| 0 — Clock basics | Wake time, light, baseline | Strong for sleep timing | Everyone |
| 1 — Magnesium L-threonate 2 g | Sleep and cognition support | C | Everyone who reaches Layer 1 |
| 2 — Epithalon 10 mg SC × 10 days | Pineal peptide | D | Optional experiment |
| 2 — Thymalin 10 mg SC × 10 days | Thymus peptide | D | Optional; adds attribution problems |
The protocol is graded D because Layer 2 is what gives it its name and what most readers came for. Layer 0 and Layer 1 on their own would be a grade C sleep protocol.
Layer 1 — Magnesium L-Threonate, From Week 2
2,000 mg magnesium L-threonate, one to two hours before bed. Three placebo-controlled trials stand behind it, all of them small and all of them run by or with the ingredient's makers:
- Older adults with cognitive impairment. In a 12-week trial of 44 people aged 50–70, overall cognitive ability improved relative to placebo (p = 0.003; Cohen's d = 0.91). Sleep and anxiety could not be judged because the placebo group improved as much. The authors worked for the company developing the compound.
- Younger adults with poor sleep. In a 6-week trial of 100 adults aged 18–45 taking 2 g/day, overall cognition improved more than on placebo (p = 0.043) and self-rated sleep impairment improved, but sleep disturbance, restorative sleep and every sleep measure from the tracking ring did not differ from placebo. The ingredient supplier funded the trial, provided the product and helped design it.
- Adults aged 35–55 with sleep problems. In a 21-day trial of 80 people taking 1 g/day, ring-measured deep-sleep and REM scores improved versus placebo. Three of the six authors were from the ingredient's supplier.
That is a consistent, modest signal with an obvious funding caveat. Profile: Magnesium L-Threonate.
Layer 2 — Epithalon and Thymalin, Labelled Honestly
Nobody needs this layer, and this page would mislead you if it said otherwise. If you run it:
- Epithalon, 10 mg subcutaneously each morning for 10 consecutive days, at most twice a year. The 10 mg is the convention vendors and forums use; the published abstracts do not report the dose given to the cohorts. Profile: Epithalon.
- Thymalin, 10 mg subcutaneously, same window — or, better, a different window. The only additional human data are the same 266-person cohort and a COVID-19 study in which adding thymalin to standard care sped the fall of IL-6, CRP and D-dimer, with no effect sizes in the abstract. Profile: Thymalin.
Run one peptide per cycle if you can. Two unapproved compounds started on the same day make any reaction impossible to attribute. Reconstitute with bacteriostatic water, rotate injection sites, and discard a vial that looks cloudy.
What Is Deliberately Left Out
- Claims of a "biological clock reset." No study has measured an epigenetic clock, telomere length or any ageing biomarker in people taking these peptides.
- Other peptides marketed alongside these (pinealon, vilon and similar "bioregulators"). Even less human data, from the same source.
- Year-round or continuous dosing. The cohorts used courses, not daily use, and nothing supports going beyond that.
- Melatonin pills as a substitute for Layer 0. They can shift timing, but they are a separate decision; see the Deep Sleep Stack.
Monitoring
| Marker | When | What you are looking for |
|---|---|---|
| Sleep diary or wearable | Weeks 0–2, then monthly | A stable wake time and sleep onset before you judge anything else |
| How you feel at 10 a.m. | Weekly, 1–5 | A sustained change of a full point; one good week is noise |
| CBC, CRP | Baseline, and 4 weeks after any peptide cycle | Unchanged. A new abnormality ends Layer 2 |
| Fasting glucose, HbA1c | Baseline, 6 months | Unchanged |
| Injection sites | Daily during a cycle | Redness, heat or a lump that grows means stop and see a clinician |
Exit Criteria
- After Layer 1 for 8 weeks, no change in sleep or daytime function: magnesium threonate is not your answer; stop it.
- After a peptide cycle, nothing changed in your diary or bloods: do not repeat it hoping the second cycle works. The evidence does not say it should.
- Any injection-site infection, allergic reaction, new lump, or a lab value that moves out of range: stop Layer 2 for good and see a clinician.
- A new cancer diagnosis or suspicion: stop everything on this page and tell your oncologist what you took.